Post-earnings recap
Reported
Thu, Feb 10, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx Pharma's earnings report indicates a significant miss on EPS, which contributed to a 4.48% drop in stock price. The lack of revenue figures and guidance adds uncertainty for investors. The company's focus on R&D suggests they are prioritizing long-term growth over short-term profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.79 | N/A | -35.40% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current financial performance and highlighted the importance of continued investment in their pipeline. They did not offer specific guidance for the upcoming quarters.
Management acknowledged challenges in achieving profitability.
They emphasized ongoing investment in research and development.
No specific guidance was provided for future performance.